Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MNKD | MannKind Corporation

IndexRUT P/E- EPS (ttm)-0.18 Insider Own2.20% Shs Outstand265.63M Perf Week-6.67%
Market Cap1.10B Forward P/E25.70 EPS next Y0.16 Insider Trans-7.91% Shs Float261.43M Perf Month-12.31%
Income-47.40M PEG- EPS next Q-0.02 Inst Own50.30% Short Float / Ratio14.97% / 13.86 Perf Quarter3.31%
Sales158.10M P/S6.95 EPS this Y-4.70% Inst Trans8.26% Short Interest39.14M Perf Half Y0.50%
Book/sh-0.98 P/B- EPS next Y328.60% ROA-15.80% Target Price6.70 Perf Year26.48%
Cash/sh0.53 P/C7.61 EPS next 5Y35.60% ROE18.90% 52W Range2.91 - 5.75 Perf YTD-22.96%
Dividend- P/FCF- EPS past 5Y21.30% ROI-50.40% 52W High-29.39% Beta1.61
Dividend %- Quick Ratio2.10 Sales past 5Y53.40% Gross Margin59.50% 52W Low39.52% ATR0.17
Employees391 Current Ratio2.40 Sales Q/Q157.10% Oper. Margin-16.90% RSI (14)30.82 Volatility4.04% 3.49%
OptionableYes Debt/Eq- EPS Q/Q82.70% Profit Margin-30.00% Rel Volume0.83 Prev Close4.11
ShortableYes LT Debt/Eq- EarningsAug 07 AMC Payout- Avg Volume2.82M Price4.06
Recom1.80 SMA20-9.08% SMA50-11.92% SMA200-10.83% Volume2,352,227 Change-1.22%
Date Action Analyst Rating Change Price Target Change
May-14-21Initiated RBC Capital Mkts Sector Perform $5
Dec-24-19Initiated Oppenheimer Outperform $2.50
Oct-25-19Initiated Cantor Fitzgerald Overweight $3
May-14-19Initiated BTIG Research Buy $3
Mar-04-19Initiated SVB Leerink Outperform $3
Feb-22-19Initiated SVB Leerink Outperform $3
Feb-28-18Downgrade Maxim Group Hold → Sell $1
Nov-01-17Downgrade Maxim Group Buy → Hold
Oct-10-17Initiated H.C. Wainwright Buy $7
Oct-06-17Reiterated Maxim Group Buy $4 → $7
Sep-07-23 07:08AM
Sep-05-23 06:00AM
Aug-28-23 06:30PM
Aug-14-23 12:44PM
Aug-08-23 05:16PM
11:33AM Loading…
Aug-07-23 06:00PM
Aug-01-23 06:00AM
Jul-31-23 04:00PM
Jul-13-23 07:31AM
06:05AM Loading…
Jun-22-23 06:05AM
Jun-11-23 08:05AM
May-28-23 07:49PM
May-24-23 08:30AM
May-23-23 09:50AM
May-10-23 12:02PM
May-09-23 11:30PM
May-02-23 05:00PM
Mar-27-23 04:05PM
02:26PM Loading…
Mar-14-23 02:26PM
Mar-07-23 05:00PM
Feb-24-23 01:30AM
Feb-23-23 04:00PM
Feb-22-23 06:05AM
Feb-16-23 05:00PM
Feb-15-23 12:46PM
Feb-10-23 05:00PM
Feb-09-23 08:50AM
Jan-24-23 06:00AM
Jan-23-23 06:05AM
Jan-18-23 08:00AM
Jan-17-23 06:36AM
Jan-05-23 06:00AM
Dec-31-22 07:11AM
Dec-06-22 09:55AM
Nov-30-22 12:29PM
Nov-10-22 06:05AM
Nov-08-22 04:30PM
Nov-01-22 06:00AM
Sep-29-22 11:38AM
Sep-21-22 05:00PM
Sep-19-22 06:00AM
Sep-08-22 01:18PM
Sep-06-22 06:15AM
Sep-01-22 06:00AM
Aug-25-22 09:09AM
Aug-19-22 06:18AM
Aug-16-22 09:03AM
Aug-10-22 07:19AM
Aug-09-22 05:15PM
Aug-02-22 06:00AM
Aug-01-22 07:35PM
Jul-26-22 10:13AM
Jun-20-22 09:28AM
Jun-03-22 10:00AM
May-25-22 10:16AM
May-24-22 06:00AM
May-19-22 06:00AM
May-17-22 06:06AM
May-09-22 06:00AM
May-06-22 01:30AM
May-05-22 05:25PM
May-04-22 06:15PM
Apr-28-22 06:00AM
Apr-27-22 10:35AM
Apr-21-22 10:38AM
Mar-28-22 06:05AM
Mar-22-22 06:05AM
Mar-08-22 06:05AM
Mar-07-22 05:59AM
Mar-03-22 05:25AM
Feb-25-22 12:30AM
Feb-24-22 04:00PM
Feb-21-22 09:05AM
Feb-10-22 06:05AM
Jan-24-22 05:38PM
Jan-11-22 07:14AM
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DP Treprostinil, an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease, and idiopathic pulmonary and cystic fibrosis. In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Castagna MichaelChief Executive OfficerSep 01Sale4.6110,00046,1002,436,039Sep 05 09:00 PM
Thomson DavidEVP Genl Counsel & SecretaryAug 28Sale4.788,10038,738798,835Aug 28 09:00 PM
Castagna MichaelChief Executive OfficerAug 01Sale4.5710,00045,6862,496,735Aug 01 09:00 PM
Castagna MichaelChief Executive OfficerJul 03Sale4.0710,00040,7012,506,735Jul 05 06:00 AM
Castagna MichaelChief Executive OfficerJun 01Sale4.5310,00045,3022,516,735Jun 02 09:00 PM
Castagna MichaelChief Executive OfficerMay 26Sale4.5075,000337,3352,526,735May 26 09:00 PM
Castagna MichaelChief Executive OfficerMay 25Sale4.5975,000344,4682,601,735May 26 09:00 PM
Castagna MichaelChief Executive OfficerMay 24Sale4.69150,000702,7802,331,735May 24 09:00 PM
Thomson DavidEVP Genl Counsel & SecretaryMay 24Sale4.6895,576447,754735,263May 24 09:00 PM
Binder Steven B.Chief Financial OfficerMay 24Sale4.6747,810223,512838,324May 24 09:00 PM
Castagna MichaelChief Executive OfficerMay 05Sale4.0010,00040,0002,020,128May 05 09:00 PM
Castagna MichaelChief Executive OfficerApr 03Sale4.1310,00041,2872,030,128Apr 05 09:00 PM
Castagna MichaelChief Executive OfficerMar 01Sale5.2710,00052,7482,040,128Mar 03 09:00 PM